Pharmacol Res. 2025 Sep:219:107894.
DOI: 10.1016/j.phrs.2025.107894. Epub 2025 Jul 31. PMID: 40752781
Claudia Pisanu, Rosana Carvalho Silva, Mattia Meattini, Massimo Gennarelli, Bernhard T Baune, Alessio Squassina, Alessandra Minelli
This systematic reviewed explored the changes in genic expression (transcriptional changes) associated with the application of ketamine and esketamine. These medications have shown a robust efficacy in the pharmacological management of treatment-resistant depression (TRD). Although the systematic review could not identify specific biomarkers associated with the use of these pharmacological treatments, transcriptional profiling revealed dynamic molecular responses to them. Such general transcriptional changes implicate neuroplastic, inflammatory, and metabolic pathways, laying the groundwork for a better understanding of the biological mechanisms underlying the antidepressant effects of ketamine and esketamine.
Read more here.
